Insulin Autoantibody Blood Test (IAA) – Type 1 Diabetes

The Insulin Autoantibody (IAA) blood test is used to detect autoantibodies directed against insulin, which are a hallmark of autoimmune-mediated destruction of pancreatic beta cells. This test is primarily requested for individuals suspected of having type 1 diabetes, those with a family history of the condition, or as part of a panel to distinguish type 1 from type 2 diabetes. It is also valuable in screening for preclinical diabetes in high-risk groups, including first-degree relatives of people with type 1 diabetes and individuals with other autoimmune conditions such as thyroid disease or coeliac disease.

Biomarkers

• Insulin autoantibody (IAA): An antibody produced by the immune system that targets insulin. Its presence indicates an autoimmune response against the insulin-producing beta cells of the pancreas, which is characteristic of type 1 diabetes. This marker can appear early in the disease process, often before clinical symptoms and before other diabetes-related autoantibodies become detectable.

Why it matters

Identifying insulin autoantibodies can help confirm a diagnosis of type 1 diabetes, predict disease progression in at-risk individuals, and guide timely clinical intervention. Early detection supports proactive management, reduces the risk of diabetic ketoacidosis at diagnosis, and informs monitoring strategies for those with a genetic or familial predisposition.